None listed
Conditions
Interventions
Sponsors
RIVM
Eligibility
Inclusion criteria
Inclusion criteria: • Participant in round 6 of the Doetinchem Cohort study and born between 1941-1947 • Willing to receive the PPV23 vaccine in 2020 • Have signed Informed Consent.
Exclusion criteria
Exclusion criteria: • Having had a previous pneumococcal vaccination • Known or suspected allergy to any of the vaccine components or having experienced a previous severe adverse reaction to any vaccine. • Receipt of any high-dose (= 20 mg of prednisone daily or equivalent) daily corticosteroids (locally applied including inhaled steroids are acceptable) within 2 weeks of study entry. • Repeated use of any high dose of corticosteroids (a dose of > 30 mg of prednisone or equivalent per day for multiple days) in the last month. • Receipt of a recent organ- or bone marrow transplant during the last 5 years . • Have an anatomical or functional asplenia. • Receipt of blood products or immunoglobulin, within one month of the study entry. • Known or suspected coagulation disorder that in the opinion of the investigator would contraindicate against receiving an intramuscular injection or undergo frequent blood sampling. • Known to be positive for human immunodeficiency virus (HIV), and/or hepatitis C virus (HCV) and/or hepatitis B virus (HBV).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assess the relation of frailty in 73-79 years old male and female persons with antibody responses to both vaccine pneumococcal polysaccharide serotypes and the Influenza virus vaccine strains by measuring HI titers pre and 4-6 weeks post vaccination. | — |
Secondary
| Measure | Time frame |
|---|---|
| • Determine the persistence of antibody responses to PPV23 related to frailty in older persons till 2 years post vaccination. • Assess baseline numbers of immune cell subsets as well as the inflammatory status at baseline and integration of these data for their association with frailty and vaccine • Assessment of inter-individual differences in biological ageing of the immune system with specific frailty characteristics or morbidities that are related to low vaccine responses. subgroups of individuals more at risk for lower vaccine responsiveness can be identified. • Monitoring possible inference of infection with COVID-19 on vaccine responsiveness by measuring virus-specific serum IgG antibodies to COVID-19 | — |
Contacts
Public ContactLinde Woudstra
RIVM
Outcome results
None listed